NCT04185415已完成1 期
A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 13
- 主要终点
- Incidence of treatment emergent adverse events (TEAEs) from Baseline to the last Visit
研究概览
简要总结
The purpose of the study is to assess the safety and tolerability of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be ≥40 years of age at the time of signing the informed consent
- •Participants meet the criteria for possible or probable Progressive Supranuclear Palsy (PSP) Richardson's Syndrome according the Movement Disorder Society (MDS)-PSP criteria
- •Participant is able to walk at least 5 steps with minimal or no assistance (stabilization of one arm or use of cane/walker)
- •Participant has reliable caregiver support during the whole study period or the participant is able to independently follow the study protocol
- •Participant is stable on all treatments for at least 2 weeks prior to the Baseline Visit
- •Participant has a body mass index (BMI) within the range 16.0 to 32.0 kg/m^2 (inclusive)
- •Participants can be male or female
- •Participant (and caregiver or legal representative, if applicable) is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent form (ICF) and in this protocol. Informed consent must be obtained before initiating any study procedures
排除标准
- •Ongoing, recurrent, severe headaches, including migraines
- •Evidence of any clinically significant neurological disorder (including any clinically significant abnormalities on the screening magnetic resonance imaging) other than Progressive Supranuclear Palsy (PSP)
- •Participant has a lifetime history of suicide attempt, or has suicidal ideation with at least some intent to act in the past 12 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Screening/Baseline" version of the Columbia-suicide severity rating scale (C-SSRS) at Screening
- •Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or medical monitor, contraindicates participation in the study
- •The following liver enzyme test results:
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) are >2.0x upper limit of normal (ULN)
- •Bilirubin >1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35 %)
- •The mean QT interval value (corrected by Fredericia's formula for the heart rate, QTcF) of the 3 Screening ECGs is >450 msec for male participants or >470 msec for female participants or QTcF is >480 msec in participants with bundle branch block
- •Abnormalities in lumbar spine previously known or determined by a Screening lumbar x-ray (if conducted) that may jeopardize the execution of the lumbar puncture
- •Participant was previously treated with tau-protein targeting drugs and/or tau-protein targeting antibodies or vaccines.
- •Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to the first dose
研究组 & 干预措施
bepranemab
Experimental
Subjects will be randomized to receive bepranemab.
干预措施: bepranemab (Drug)
Placebo
Placebo Comparator
Subjects will be randomized to receive Placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of treatment emergent adverse events (TEAEs) from Baseline to the last Visit
时间窗: From Baseline up to Week 68
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
次要结局
未报告次要终点
研究者
研究点 (13)
Loading locations...
相似试验
已完成
2 期
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's DiseaseEarly-stage Parkinson's DiseaseNCT04658186UCB Biopharma SRL496
已完成
1 期
Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy SubjectsHealthy VolunteersNCT02207595UCB Celltech60
已完成
1 期
Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic SubjectPsoriasisNCT02303509UCB Pharma57
已完成
1 期
A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male SubjectsHealthy Male VolunteersNCT03464227UCB Biopharma S.P.R.L.52
已完成
1 期
A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's DiseaseHealthy Study ParticipantsParkinson's DiseaseNCT04867642UCB Biopharma SRL100